Clinical Trial

Vita Global Sciences Partners with Veeva to Streamline Clinical Data Management

CRO will use Veeva Vault EDC to deliver a better experience to patients, research sites, and sponsors PLEASANTON, Calif., June…

1 year ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain…

1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…

1 year ago

Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise…

1 year ago

Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…

1 year ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology…

1 year ago

Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a…

1 year ago

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic…

1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage…

1 year ago